Table 3. Univariate analysis of disease-free survival.
| Variable | 3-year DFS (%) | P-value |
|---|---|---|
|
Sex | ||
| Male | 85.0 | 0.66 |
| Female |
83.8 |
|
|
Age | ||
| ⩾65 years | 85.7 | 0.82 |
| <65 years |
83.9 |
|
|
Location | ||
| Proximal | 87.0 | 0.25 |
| Distal |
83.1 |
|
|
Stage | ||
| II | 86.8 | 0.35 |
| III |
84.1 |
|
|
T stage | ||
| T1–3 | 86.8 | 0.003 |
| T4 |
73.9 |
|
|
N stage | ||
| N0–1 | 89.4 | <0.001 |
| N2 |
72.6 |
|
|
Angiolymphatic invasion | ||
| Present | 75.4 | <0.001 |
| Absent |
91.2 |
|
|
Venous invasion | ||
| Present | 71.0 | 0.003 |
| Absent |
86.6 |
|
|
Perineural invasion | ||
| Present | 74.3 | <0.001 |
| Absent |
87.8 |
|
|
Histology | ||
| MAC | 57.4 | <0.001 |
| Non-MAC* |
86.3 |
|
|
Microsatellite status | ||
| MSS/MSI-L | 84.1 | 0.46 |
| MSI-H | 90.0 | |
Abbreviations: DFS=disease-free survival; MAC=mucinous adenocarcinoma; MSI-H=high microsatellite instability; MSI-L=low microsatellite instability; MSS=microsatellite stable.
*Non-MAC includes non-mucinous adenocarcinoma and adenocarcinoma with intermediate mucinous component.